
    
      Subjects aged 9 months through 55 years and who are given study vaccine during routine
      health-care visits will be enrolled in the study.

      They will be followed-up for up to Day 42 following vaccination.

      No study vaccine will be supplied or administered as part of this study, subjects will be
      monitored following routine vaccine administration in clinical settings.
    
  